{Reference Type}: Journal Article
{Title}: [Risk minimalisation measures for medications; are they incorporated in Dutch clinical guidelines?]
{Author}: Grupstra RJ;Siiskonen SJ;Gardarsdottir H;
{Journal}: Ned Tijdschr Geneeskd
{Volume}: 168
{Issue}: 0
{Year}: 2024 Jun 25
暂无{Abstract}: <B>OBJECTIVE: </B>Risk minimisation measures (RMM) are put in place to ensure safe and effective use of medicines. This study assessed whether RMM for five medicines are implemented in Dutch clinical guidelines.<BR><B>METHODS: </B>Descriptive study.<BR><B>METHODS: </B>Dutch clinical guidelines where treatment with valproate, fluoroquinolones, methotrexate, metformin or fluorouracil was recommended were identified. In those guidelines that had been updated after publication of the RMM, we determined whether RMM-information was included in the guideline.<BR><B>RESULTS: </B>Out of 50 identified guidelines recommending treatment with one of the five medicines, only 21 (42%) were revised after RMM-implementation. Of these 21 guidelines, 12 (n = 57%) included RMM-related information.<BR><B>CONCLUSIONS: </B>Uptake of RMM information in Dutch clinical guidelines is limited and RMM-publication does not prompt guideline updates. This suggests that guidelines alone are not an optimal way to inform health care professionals of new safety warnings.